Skip to main content


Glomerulonephritis (GN) is a group of kidney diseases which while relatively rare, represent the second most common cause of end-stage renal disease in Canada. GN appears to be increasing in prevalence and disproportionately affecting younger Canadians. Along with our GN Network and Registry and international collaborators, our research aims to identify risks and address gaps and barriers to best care for GN patients. 

Publications and Presentations


  1. ‎Canney M, Induruwage D, Sahota A, McCrory C, Hladunewich M A, Gill J, Barbour S. (2020). Socioeconomic Position and Incidence of Glomerular Diseases. CJASN, Feb 2020.
  1. Barbour S, Coppo R, Zhang H, Liu Z, Matsuzaki K, Katafuchi R, Er L, Espino-Hernandez G, S. Kim J, Reich H N, Feehally J, Cattran D C. (2019). Evaluating a new international risk prediction tool in IgA Nephropathy. JAMA Intern Med. April 2019.
  2. ‎Canney M, Induruwage D, McCandless LC, Reich H, Barbour S. (2019). Disease-specific incident glomerulonephritis displays geographic clustering in under-serviced rural areas of British Columbia, Canada. Kidney International.
  3. Waheed A, Djurdjev O, Dong J, Gill J, Barbour S. (2019). Validation of Self-Reported Race in a Canadian Provincial  Renal Administrative Database. Canadian J Kidney Health Dis. July 2019.
  1. Barbour S, Lo C, Espino-Hernandez G, Gill J, Levin A. (2018). The BC Glomerulonephritis Network: Improving Access and Reducing the Cost of Immunosuppressive Treatments for Glomerular Diseases, CJKHD, March 20 2018.
  2. Harris C, Marin J, Beaulieu M C. (2018). Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report. BMC Nephrology, 19: 152.

  1. Barbour S, Feehally J. (2017). An update on the treatment of IgA nephropathy. Current Opinion in Nephrology and Hypertension. 26(4):319-326.
  2. Barbour S, Lo C, Espino-Hernandez G, Sajjadi S, Feehally J, Klarenbach S, Gill J S. (2017). The population-level costs of immunosuppression medications for the treatment of glomerulonephritis are increasing over time due to changing patterns of practice. Nephrol Dial Transplant (2017) 1–9.
  3. Hutton HL, Levin A, Gill J, Djurdjev O, Tang M, Barbour SJ. (2017). Cardiovascular risk is similar in patients with glomerulonephritis compared to other types of chronic kidney disease: a matched cohort study. Bmc Nephrology.18:10.
  1. Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J, Herzenberg AM, Cattran DC, Derivation O, Valiga Consortia. (2016). The MEST score provides earlier risk prediction in lgA nephropathy. Kidney international.89(1):167-75.
  2. Gu B, Magil AB, Barbour SJ. (2016). Frequently relapsing anti-glomerular basement membrane antibody disease with changing clinical and phenotype and antibody characteristics over time. Clinical kidney journal.9(5):661-664.
  3. Mann S, Seidman MA, Barbour SJ, Levin A, Carruthers M, Chen LY. (2016). Recognizing IgG4-related tubulointerstitial nephritis. Canadian journal of kidney health and disease.3:34.
  1. Barbour S, Gill JS. (2015). Advances in the understanding of complement mediated glomerular disease: implications for recurrence in the transplant setting. American journal of transplantation. 15(2): 312-9 
  2. Barbour, SJ, Cattran, DC, Espino-Hernandez, G, Hladunewich, MA, Reich, HN. (2015). Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis. Kidney Int, 88(6), 1392-1401.
  3. Fervenza, FC, Canetta, PA, Barbour, SJ, Lafayette, RA, Rovin, BH, Aslam, N, Hladunewich, MA, Irazabal, MV, Sethi, S, Gipson, DS, Reich, HN, Brenchley, P, Kretzler, M, Radhakrishnan, J, Hebert, LA, Gipson, PE, Thomas, LF, McCarthy, ET, Appel, GB, Jefferson, JA, Eirin, A, Lieske, JC, Hogan, MC, Greene, EL, Dillon, JJ, Leung, N, Sedor, JR, Rizk, DV, Blumenthal, SS, Lasic, LB, Juncos, LA, Green, DF, Simon, J, Sussman, AN, Philibert, D, Cattran, DC, Global Mentor Consortium. (2015). A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR)', Nephron, (1303), 159-168.
  4. Hogg RJ, Bay RC, Jennette JC, Sibley R, Kumar S, Fervenza FC, Appel G, Cattran D, Fischer D, Hurley RM, Cerda J. (2015). Randomized Controlled Trial of Mycophenolate Mofetil in Children, Adolescents, and Adults With IgA Nephropathy. American Journal of Kidney Diseases. 66(5):783-91.
  1. Barbour, S, Beaulieu, M, Gill, J, Espino-Hernandez, G, Reich, HN, Levin, A. (2014). The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists. Clin Kidney J, 7(6), 538-45.
  2. Lee, T, Biddle, AK, Lionaki, S, Derebail, VK, Barbour, SJ, Tannous, S, Hladunewich, MA, Hu, YC, Poulton, CJ, Mahoney, SL, Jennette, JC, Hogan, SL, Falk, RJ, Cattran, DC, Reich, HN, Nachman, PH. (2014). Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. Kidney International, 85(6), 1412-1420.
  1. Barbour S, Beaulieu M, Gill J, Djurdjev O, Reich H, Levin A. An overview of the British Columbia Glomerulonephritis network and registry: integrating knowledge generation and translation within a single framework. BMC nephrology. 14(1).
  2. Barbour S, Reich H, Cattran D. Short-term complications of membranous nephropathy. Contributions to Nephrology. 181.
  3. Barbour SJ, Cattran DC, Kim SJ, Levin A, Wald R, Hladunewich MA, Reich HN. (2013). Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney international. 84(5):1017-24.
  1. Barbour S, Greenwald A, Djurdjev O, Levin A, et al. Disease-specific risk venous thromboembolic events in idiopathic glomerulonephritis. KI, Jan 2012; 81(2):190-5.
  2. Barbour SJ, Reich HN. Risk stratification of patients with IgA nephropathy. American Journal of Kidney Diseases. 59(6).
  3. Lionaki S, Derebail VK, Hogan SL, Barbour S, et al. Venous thromboembolism in patients with membranous nephropathy. Clinical Journal of the American Society of Nephrology. 7(1).
  4. Lv J, Perkovic V, Ma X, Johnson D, Woodward M, Levin A, Zhang H, Wang H. Corticosteroid Therapy in IgA Nephropathy. JASN. Apr 2012; 23:1108-16. 
  1. Barbour SJ, Beaulieu MC, Zalunardo NY, Magil AB. (2011). Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases. Nephrol Dial Transplant. 26(8):2712-4.   

  1. Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis. 2010 Jan;55(1):50-60.
  2. Schachter ME, Monahan M, Radakrishnan J, Crew J, Pollak M, Ratner L, Valeri AM, Stokes BM, Appel GB. (2010). Recurrent focal segmental glomerulosclerosis in the renal allograft: Single center experience in the era of modern immunosuppression. Clinical Nephrology. [Epub ahead of print]. 


  1. The BC Provincial Renal Agency’s Glomerulonephritis Formulary 
    Team: Clifford Lo, Sean Barbour, Dan Martinusen, Monica Beaulieu, Adeera Levin

  1. The Risk of Cardiovascular Events in Patients with Advanced Glomerulonephritis Is Not Higher Than Those with Other Causes of Chronic Kidney Disease
    Organizations: Monash University; University of British Columbia; BC Provincial Renal Agency
    Team: Holly L. Hutton, Adeera Levin, Jagbir Gill, Ognjenka Djurdjev, Sean Barbour
  1. Care gaps and barriers to guideline-based management of glomerulonephritis: a survey of nephrologists
    Organizations:  Division of Nephrology, University of BC; BC Provincial Renal Agency; Division of Nephrology, University of Toronto
    Team: Sean Barbour; Monica C. Beaulieu; Jagbir Gill; Heather N. Reich; Adeera Levin
  2. Proteinuria does not need to be standardized to body surface area in adults with glomerulonephritis
    Organization: Division of Nephrology, University of British Columbia; BC Provincial Renal Agency; Division of Nephrology, University of Toronto
    Team: Sean Barbour; Daniel C. Cattran; Gabriela Espino-Hernandez; Michelle A. Hladunewich; Adeera Levin; Heather N. Reich

Tab Heading
Tab Heading
SOURCE: Glomerulonephritis ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Renal Agency. All Rights Reserved.

    Copyright © 2021 Provincial Health Services Authority